Facebook
Twitter
LinkedIn
ForwardMultiple Myeloma & Lymphoma Summit
This CME-accredited activity Multiple Myeloma & Lymphoma Summit features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to, CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.
Platinum Sponsor
Janssen Biotech, Inc.
Bronze Sponsor
Legend Biotech
Target Audience
- Practicing medical oncologists/hematologists
- Pathologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
Hotel Information
A limited number of rooms have been reserved for the attendees of this conference at the DoubleTree by Hilton Park City – The Yarrow at a discounted rate of $129/night.
Reserve your room at the following link by the cutoff date Tuesday, April 19, 2023, to receive the discounted rate: https://group.doubletree.com/8pxhfa
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review strategies for induction, autologous transplantation, and maintenance therapy for patients with newly diagnosed multiple myeloma
- Outline efficacy and toxicities of monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with relapsed and refractory multiple myeloma
- Review CAR-T, bispecific antibodies, and antibody drug conjugates in management of DLBCL patients
- Apply an individualized treatment plan for patients with early/advanced stage cHL and T cell lymphomas
- List indications and toxicity profile of novel targeted agents in management of indolent lymphomas including CLL, FL, MCL
- Review the indications for the treatment of Waldenström Macroglobulinemia and current therapeutic strategies
Conference Co-Chairs: Dr. Harsh Shah & Dr. Douglas Sborov
May 20, 2023
07:00 AM - 07:45 AM Breakfast, Exhibits, and Registration
07:50 AM – 08:00 AM Welcome remarks
08:00 AM - 09:15 AM Session 1: Newly Diagnosed Multiple Myeloma: How Much and for How Long?
08:00 AM - 08:20 AM Transplant Ineligible Disease: Is there a role for proteasome inhibitors? - Douglas Sborov, MD MS
08:20 AM – 08:40 AM The Role of Quadruplet Therapy for All Newly Diagnosed Patients - Ghulam (Manni) Mohyuddin, MD
08:40 AM - 09:00 AM Maintenance Therapy: Drug Choice and Duration of Treatment - Craig Hofmeister, MD, MPH
09:00 AM - 09:15 AM Case-based panel discussion with Dane Osborn, MD
09:15 AM - 10:30 AM Session 2: Relapsed and Refractory Multiple Myeloma and Emerging Immunotherapies
09:15 AM - 09:35 AM What to Use and When: Drug Sequencing in Relapsed and Refractory Multiple Myeloma - Amandeep Godara, MD
09:35 AM - 09:55 AM CAR-T and T-cell Redirecting Bispecific Antibodies in Multiple Myeloma - Brian McClune, DO
09:55 AM - 10:15 AM New and Exciting Therapeutics: An ASH Update! - Craig Hofmeister, MD, MPH
10:15 AM - 10:30 AM Case-based panel discussion with Gliceida Galarza Fortuna, MD
10:30 AM - 10:45 AM Break & Exhibit Visits
10:45 AM - 12:20 PM Session 3: Management of Patients with Indolent Lymphomas with Immunotherapy and Targeted Agents
10:45 AM - 11:05 AM Treatment Updates in Waldenström Macroglobulinemia - Amandeep Godara, MD
11:05 AM - 11:25 AM Frontline management of patients with CLL in the era of targeted agents - Deborah Stephens, DO
11:25 AM - 11:45 AM Updates in the management of patients with MCL in frontline and relapsed/refractory setting - Daniel A. Ermann, MD
11:45 AM - 12:05 PM Emerging role of immunotherapy and targeted agents in the management of FL (including CAR T) - Wayne Ormsby, MD
12:05 PM - 12:20 PM Case-based panel discussion with Taylor Kujawa, PharmD
12:20 PM - 01:30 PM Lunch & Exhibit Viewing
12:30 PM - 1:15 PM Product theater sponsored by AstraZeneca - Use of a Targeted Agent For Previously Untreated or R/R CLL - Dr. Callie Coombs - this non-CME activity will take place in the Ivers Room
01:30 PM - 02:45 PM Session 4: Management of Patients with Aggressive Lymphomas with Immunotherapy and Targeted Agents
01:30 PM - 01:50 PM Frontline treatment of patients with DLBCL - Lindsey Fitzgerald, MD
01:50 PM - 02:10 PM CAR-T updates in DLBCL - Indumathy Varadarajan, MBBS
02:10 PM - 02:30 PM The role of other immunotherapies (Bi-specifics, ADCs, ASCT) in DLBCL - Dipenkumar Modi, MD
02:30 PM - 02:45 PM Case-based panel discussion with Daniel A. Ermann, MD
02:45 PM - 04:00 PM Session 5: Management of Hodgkin Lymphoma and T-cell Lymphomas
02:45 PM - 03:05 PM Frontline Management of patients with early stage and Advanced cHL - Boyu Hu, MD
03:05 PM - 03:25 PM Immunotherapy in relapsed/refractory cHL - Harsh Shah, DO
03:25 PM - 03:45 PM Updates in cutaneous T cell Lymphomas - Ahmad Halwani, MD
03:45 PM - 04:00 PM Case-based panel discussion with Charlotte Wagner, PharmD
04:00 PM Concluding remarks
A limited number of rooms have been reserved for the attendees of this conference at the DoubleTree by Hilton Park City – The Yarrow at a discounted rate of $129/night.
Reserve your room at the following link by Tuesday, April 19, 2023, to receive the discounted rate: https://group.doubletree.com/8pxhfa
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Douglas Sborov, MD MS
Harsh Shah, D.O.
Douglas Sborov, MD MS
Harsh Shah, D.O.
Daniel Ermann, Medical Doctor
Lindsey Fitzgerald, MD
Gliceida Galarza Fortuna
Amandeep Godara, MD
Ahmad Halwani, M.D.
Craig Hofmeister, MD
Boyu Hu
Taylor Kujawa, PharmD
Brian McClune, DO
Dipenkumar Modi, M.D.
Ghulam Rehman Mohyuddin, MD
Wayne Ormsby, MD
Dane Osborn, MD
Douglas Sborov, MD MS
Harsh Shah, D.O.
Deborah Stephens, DO
Indumathy Varadarajan, MBBS
Charlotte Wagner, PharmD, BCOP
Available Credit
- 5.25 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 5.25 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 5.25 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.25 Contact Hours.
Price
REGISTRATION FEES
Physicians (non-industry) - $200
Non-physician HCP (non-industry) - $75
Industry representatives - $850 (early-bird rate if registered on or before 5/8/23), $1050 starting on 5/9/23; $1250 on-site
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.